Resveratrol in Patients with Minimal Hepatic Encephalopathy

Area of Science:

• Hepatology
• Nutraceuticals
• Clinical Medicine

Background:

• Minimal Hepatic Encephalopathy (MHE) is a condition affecting social interaction, mood, sleep, and overall quality of life.
• MHE patients often experience physical and mental symptoms impacting their daily functioning.
• Current understanding of MHE's impact on quality of life (QoL) necessitates further investigation into therapeutic interventions.

Purpose of the Study:

• To evaluate the liver health-promoting potential of Resveratrol (RV).
• To assess the efficacy of RV in improving health-related quality of life (HRQL) in MHE patients.
• To determine if RV treatment can reduce depression and anxiety symptoms in individuals with MHE.

Main Methods:

• A randomized study involving 70 MHE patients was conducted.
• Participants were assessed for depression (Beck Depression Inventory), anxiety (State-trait anxiety inventory), and quality of life (SF-36).
• Serum ammonia levels were also measured in both Resveratrol and placebo groups.

Main Results:

• Resveratrol treatment led to significant reductions in depression (BDI) and anxiety (STAI) scores (p < 0.001).
• Patients receiving Resveratrol showed significant improvements in multiple SF-36 domains, including physical function, general health, and social function (p < 0.001).
• Improvements were also noted in role physical, body pain, and vitality scores for the Resveratrol group (p < 0.05).

Conclusions:

• Resveratrol demonstrated significant efficacy in treating depression and anxiety associated with MHE.
• RV treatment effectively improved the quality of life for patients suffering from MHE.
• Resveratrol also showed a positive impact on reducing serum ammonia levels in MHE patients.